Etalocib (sodium)
Etalocib (LY293111) sodium, an orally active leukotriene B4 receptor antagonist, inhibits the binding of [3H]LTB4, with a Ki of 25 nM. Etalocib sodium prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib sodium induces apoptosis[1][2][3].
Product Specifications
CAS Number
152608-41-8
Product Name Alternative
LY293111 (sodium) ; VML 295 (sodium)
UNSPSC
12352101
Target
Apoptosis; Leukotriene Receptor
Type
Reference compound
Related Pathways
Apoptosis; GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/etalocib-sodium.html
Smiles
O=C(C1=C(OC2=CC=CC(OCCCOC3=C(CC)C=C(C4=CC=C(F)C=C4)C(O)=C3)=C2CCC)C=CC=C1)O[Na]
Molecular Formula
C33H32FNaO6
Molecular Weight
566.59
References & Citations
[1]P Marder, et al. Blockade of Human Neutrophil Activation by 2-[2-propyl-3-[3-[2-ethyl-4- (4-fluorophenyl) -5- Hydroxyphenoxy]propoxy]phenoxy]benzoic Acid (LY293111), a Novel Leukotriene B4 Receptor Antagonist. Biochem Pharmacol. 1995 May 26;49 (11) :1683-90.|[2] S A Silbaugh, et al. Pharmacologic Actions of the Second Generation Leukotriene B4 Receptor Antagonist LY29311: In Vivo Pulmonary Studies. Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361 (4) :397-404.|[3]Wei-Gang Tong, et al. Leukotriene B4 Receptor Antagonist LY293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells. Clin Cancer Res. 2002 Oct;8 (10) :3232-42.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
LTB4
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680669-500 1x 500 µL
P27 / KIP1 (SX53G8), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040253-100 1x 100 µL
Cytokeratin, LMW (AE-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400841-100 1x 100 µL
Pgp9.5 (UCHL-1) (UCHL1/841), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details